These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 22860209)

  • 1. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
    Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
    ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
    Sagredo O; Pazos MR; Satta V; Ramos JA; Pertwee RG; Fernández-Ruiz J
    J Neurosci Res; 2011 Sep; 89(9):1509-18. PubMed ID: 21674569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
    Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
    Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
    Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
    Sagredo O; González S; Aroyo I; Pazos MR; Benito C; Lastres-Becker I; Romero JP; Tolón RM; Mechoulam R; Brouillet E; Romero J; Fernández-Ruiz J
    Glia; 2009 Aug; 57(11):1154-67. PubMed ID: 19115380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
    Lastres-Becker I; Bizat N; Boyer F; Hantraye P; Brouillet E; Fernández-Ruiz J
    Neuroreport; 2003 May; 14(6):813-6. PubMed ID: 12858038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.
    Moreno-Martet M; Espejo-Porras F; Fernández-Ruiz J; de Lago E
    CNS Neurosci Ther; 2014 Sep; 20(9):809-15. PubMed ID: 24703394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
    Feliú A; Moreno-Martet M; Mecha M; Carrillo-Salinas FJ; de Lago E; Fernández-Ruiz J; Guaza C
    Br J Pharmacol; 2015 Jul; 172(14):3579-95. PubMed ID: 25857324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
    Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
    Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
    García C; Palomo-Garo C; García-Arencibia M; Ramos J; Pertwee R; Fernández-Ruiz J
    Br J Pharmacol; 2011 Aug; 163(7):1495-506. PubMed ID: 21323909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
    Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
    Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.
    Valdeolivas S; Pazos MR; Bisogno T; Piscitelli F; Iannotti FA; Allarà M; Sagredo O; Di Marzo V; Fernández-Ruiz J
    Cell Death Dis; 2013 Oct; 4(10):e862. PubMed ID: 24136226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocannabinoid system in Huntington's disease.
    Pazos MR; Sagredo O; Fernández-Ruiz J
    Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids: novel medicines for the treatment of Huntington's disease.
    Sagredo O; Pazos MR; Valdeolivas S; Fernandez-Ruiz J
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):41-8. PubMed ID: 22280340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
    Pertwee RG
    Br J Pharmacol; 2009 Feb; 156(3):397-411. PubMed ID: 19226257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
    Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
    J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
    Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
    Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.